RESUMO
Background and Objectives: The ineffective combination of corticosteroids and antibiotics in treating some atopic dermatitis (AD) cases has been concerning. The skin barrier defects in AD ease the colonization of Staphylococcus aureus (S. aureus), which results in a rise in interleukin-31 (IL-31). Lumbricus rubellus (L. rubellus) has shown antimicrobial and antiallergic effects but has not been studied yet to decrease the growth of S. aureus and IL-31 levels in AD patients. This study aimed to analyze the effect of L. rubellus extract in reducing S. aureus colonization, the IL-31 level, and the severity of AD. Materials and Methods: A randomized controlled trial (RCT) (international registration number TCTR20231025004) was conducted on 40 AD patients attending Dermatology and Venereology Polyclinic, Mother and Child Hospital (RSIA), Aceh, Indonesia, from October 2021 to March 2022. AD patients aged 8-16 who had a Scoring Atopic Dermatitis (SCORAD) index > 25, with total IgE serum level > 100 IU/mL, and had healthy weight were randomly assigned into two groups: one received fluocinolone acetonide 0.025% and placebo (control group) and one received fluocinolone acetonide 0.025% combined with L. rubellus extract (Vermint®) (intervention group). The S. aureus colony was identified using a catalase test, coagulase test, and MSA media. The serum IL-31 levels were measured using ELISA assay, while the SCORAD index was used to assess the severity of and improvement in AD. Mean scores for measured variables were compared between the two groups using an unpaired t-test and Mann-Whitney U test. Results: A significant decline in S. aureus colonization (p = 0.001) and IL-31 (p = 0.013) in patients receiving L. rubellus extract was found in this study. Moreover, fourteen AD patients in the intervention group showed an improvement in the SCORAD index of more than 35% (p = 0.057). Conclusions: L. rubellus extract significantly decreases S. aureus colonization and the IL-31 level in AD patients, suggesting its potential as an adjuvant therapy for children with AD.
Assuntos
Dermatite Atópica , Oligoquetos , Infecções Estafilocócicas , Criança , Humanos , Animais , Dermatite Atópica/tratamento farmacológico , Staphylococcus aureus , Interleucinas , Fluocinolona Acetonida/farmacologia , Fluocinolona Acetonida/uso terapêutico , Índice de Gravidade de DoençaRESUMO
Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non-infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
Assuntos
Retinopatia Diabética , Fluocinolona Acetonida , Edema Macular , Doenças Retinianas , Humanos , Retinopatia Diabética/tratamento farmacológico , Implantes de Medicamento/uso terapêutico , Fluocinolona Acetonida/administração & dosagem , Fluocinolona Acetonida/farmacologia , Fluocinolona Acetonida/uso terapêutico , Glucocorticoides/uso terapêutico , Injeções Intravítreas , Edema Macular/tratamento farmacológico , Doenças Retinianas/tratamento farmacológico , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêuticoRESUMO
INTRODUCTION: Sustained-release corticosteroid implants are injected into the vitreous cavity using preloaded pens. The fluocinolone (FAc) implant is approximately half the size of the dexamethasone implant (Dex-I). It is simply introduced in the vitreous base rather than propelled into the vitreous cavity as is Dex-I. Verification of its positioning after injection is thus difficult by indirect ophthalmoscopy. The goal of our study is to compare the performance of available clinical and imaging tools to confirm the presence of the FAc in the vitreous cavity following injection. METHODS: Twelve eyes of 12 consecutive patients were included in a retrospective, single-center, observational study carried out at the Bordeaux University Hospital, France. All patients were injected with the FAc after pupil dilation, and presence of the implant was immediately checked by indirect biomicroscopy, wide-field retinography (Clarus®, Carl-Zeiss-Meditec, Dublin, CA, USA) and ultra-wide-field retinography (California®, Optos, Edinburgh, United-Kingdom). Seven days later, a B-mode ultrasonography (10MHz, AVISO, Quantel-medical, France) and an UBM ultrasonography (50MHz, AVISO, Quantel-medical, France) were performed. RESULTS: Indirect biomicroscopy and wide-field retinography detected 4/12 implants (33.3%). Ultra-wide-field retinophotography detected 6/12 implants (50%). All the implants seen using indirect biomicroscopy and wide-field retinography were also visualized with ultra-wide-field. B-mode ultrasonography showed 5/12 implants (41.6%) and UBM 9/12 implants (75%). Finally, one implant dislocated into the anterior chamber and was seen in the iridocorneal angle on gonioscopy. CONCLUSION: Objective confirmation of the proper positioning of the FAc implant in the vitreous cavity is mandatory. If both indirect ophthalmoscopy and anterior examination fail to detect it, ultra-wide field retinography along with UBM ultrasonography, if necessary, appear to be the two best imaging modalities to use.
Assuntos
Retinopatia Diabética , Edema Macular , Humanos , Fluocinolona Acetonida/farmacologia , Fluocinolona Acetonida/uso terapêutico , Glucocorticoides/farmacologia , Glucocorticoides/uso terapêutico , Retinopatia Diabética/tratamento farmacológico , Estudos Retrospectivos , Edema Macular/tratamento farmacológico , Implantes de Medicamento , Injeções IntravítreasRESUMO
While topical corticosteroid (TCS) treatment is widely used for many skin diseases, it can trigger adverse side effects, and some of such effects can last for a long time after stopping the treatment. However, molecular changes induced by TCS treatment remain largely unexplored, although transient changes in histology and some major ECM components have been documented. Here, we investigated transcriptomic and proteomic changes induced by fluocinolone acetonide (FA) treatment in the mouse skin by conducting RNA-Seq and quantitative proteomics. Chronic FA treatment affected the expression of 4229 genes, where downregulated genes were involved in cell-cycle progression and ECM organization, and upregulated genes were involved in lipid metabolism. The effects of FA on transcriptome and histology of the skin largely returned to normal by two weeks after the treatment. Only a fraction of transcriptomic changes were reflected by proteomic changes, and the expression of 46 proteins was affected one day after chronic FA treatment. A comparable number of proteins were differentially expressed between control and FA-treated skin samples even at 15 and 30 days after stopping chronic FA treatment. Interestingly, proteins affected during and after chronic FA treatment were largely different. Our results provide fundamental information of molecular changes induced by FA treatment in the skin.
Assuntos
Fluocinolona Acetonida , Transcriptoma , Camundongos , Animais , Fluocinolona Acetonida/farmacologia , Fluocinolona Acetonida/uso terapêutico , Proteômica , Pele/metabolismo , Glucocorticoides/metabolismo , Corticosteroides/metabolismoRESUMO
OBJECTIVE: Tympanic membrane (TM) fibroblast cytotoxicity of quinolone ear drops is enhanced by dexamethasone and fluocinolone. Hydrocortisone has not been evaluated. We aimed to assess the effects of these 3 steroids on mouse and human TM fibroblast survival. STUDY DESIGN: In vitro. SETTING: Academic laboratory. SUBJECTS AND METHODS: Mouse and human TM fibroblasts were exposed to hydrocortisone, dexamethasone, or fluocinolone at concentrations in commercial ear drops (1%, 0.1%, or 0.025%, respectively) and at steroid potency equivalents (1%, 0.033%, or 0.0033%, respectively), or dilute ethanol (control), twice within 24 hours or 4 times within 48 hours for 2 hours each time. Cells were observed with phase-contrast microscopy until the cytotoxicity assay was performed. RESULTS: Mouse and human TM fibroblasts treated with any of the steroids had lower survival after 24 and 48 hours compared to control (all P < .0001). After 24 hours, viability of mouse fibroblasts treated with the steroids was not different (P > .05), while treatment with hydrocortisone decreased human TM fibroblast viability (P < .0001). After 48 hours, at concentrations found in ear drops and at equivalent steroid potency, dexamethasone and fluocinolone had similar survival in mouse and human fibroblasts (all P > .05), but hydrocortisone had lower survival in both mouse (P = .02 and P < .0001) and human (P < .0001) fibroblasts. Phase-contrast images mirrored the cytotoxicity findings. CONCLUSION: Steroids found in commercial ear drops reduce survival of mouse and human TM fibroblasts. Hydrocortisone appears to be more cytotoxic than the more potent steroids, dexamethasone and fluocinolone. These findings should be considered when assessing clinical outcomes of ototopical preparations.
Assuntos
Dexametasona/farmacologia , Fibroblastos/efeitos dos fármacos , Fluocinolona Acetonida/análogos & derivados , Glucocorticoides/farmacologia , Hidrocortisona/farmacologia , Membrana Timpânica/citologia , Animais , Sobrevivência Celular , Células Cultivadas , Fluocinolona Acetonida/farmacologia , Humanos , CamundongosRESUMO
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.
Assuntos
Inibidores da Angiogênese/farmacologia , Anti-Inflamatórios/farmacologia , Retinopatia Diabética/terapia , Implantes de Medicamento/química , Fluocinolona Acetonida/farmacologia , Edema Macular/terapia , Inibidores da Angiogênese/farmacocinética , Anti-Inflamatórios/farmacocinética , Retinopatia Diabética/complicações , Retinopatia Diabética/metabolismo , Retinopatia Diabética/fisiopatologia , Fluocinolona Acetonida/farmacocinética , Humanos , Injeções Intravítreas , Fotocoagulação/métodos , Terapia com Luz de Baixa Intensidade/métodos , Edema Macular/etiologia , Edema Macular/metabolismo , Edema Macular/fisiopatologia , Segurança do Paciente , Resultado do Tratamento , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Fator A de Crescimento do Endotélio Vascular/metabolismoRESUMO
Human immunodeficiency virus (HIV) continues to be a major contributor to morbidity and mortality worldwide, particularly in developing nations where high cost and logistical issues severely limit the use of current HIV therapeutics. This, combined HIV's high propensity to develop resistance, means that new antiviral agents against novel targets are still urgently required. We previously identified novel anti-HIV agents directed against the nuclear import of the HIV integrase (IN) protein, which plays critical roles in the HIV lifecycle inside the cell nucleus, as well as in transporting the HIV preintegration complex (PIC) into the nucleus. Here we investigate the structure activity relationship of a series of these compounds for the first time, including a newly identified anti-IN compound, budesonide, showing that the extent of binding to the IN core domain correlates directly with the ability of the compound to inhibit IN nuclear transport in a permeabilised cell system. Importantly, compounds that inhibited the nuclear transport of IN were found to significantly decrease HIV viral replication, even in a dividing cell system. Significantly, budesonide or its analogue flunisolide, were able to effect a significant reduction in the presence of specific nuclear forms of the HIV DNA (2-LTR circles), suggesting that the inhibitors work though blocking IN, and potentially PIC, nuclear import. The work presented here represents a platform for further development of these specific inhibitors of HIV replication with therapeutic and prophylactic potential.
Assuntos
Transporte Ativo do Núcleo Celular/efeitos dos fármacos , Budesonida/farmacologia , Inibidores de Integrase de HIV/farmacologia , Integrase de HIV/metabolismo , HIV/efeitos dos fármacos , HIV/enzimologia , Integração Viral/efeitos dos fármacos , Animais , Budesonida/química , Linhagem Celular , Fluocinolona Acetonida/análogos & derivados , Fluocinolona Acetonida/química , Fluocinolona Acetonida/farmacologia , Inibidores de Integrase de HIV/química , Humanos , Ligação Proteica , Ratos , Relação Estrutura-Atividade , Replicação Viral/efeitos dos fármacosRESUMO
Inflammation plays an important role in all stages of atherosclerosis development. Therefore, the use of anti-inflammatory drugs could reduce the risk of major adverse cardiovascular events due to atherosclerosis. Herein, we explored the capacity of fluocinolone acetonide (FA), a glucocorticoid (GC), in modulating foam cell formation and response. Human THP-1 derived foam cells were produced using 100 µg/mL oxidized low-density lipoproteins (OxLDL) and fetal bovine serum (1 and 10%). 2D cultures of these cells were treated with FA (0.1, 1, 10, and 50 µg/mL) in comparison with dexamethasone (Dex). Results showed that treatment with 0.1 and 1 µg/mL FA and Dex improved foam cell survival. FA and Dex also inhibited inflammatory cytokine (CD14, M-CSF, MIP-3α, and TNF-α) secretion. Notably, at the concentration of 1 µg/mL, both FA and Dex reduced cholesteryl ester accumulation. Compared to Dex, FA was significantly better in reducing lipid accumulation at the therapeutic concentrations of 1 and 10 µg/mL. In a novel 3D foam cell spheroid model, FA was shown to be more effective than Dex in diminishing lipid accumulation, at the concentration of 0.1 µg/mL. Taken together, FA was demonstrated to be effective in preventing both lipid accumulation and inflammation in foam cells.
Assuntos
Fluocinolona Acetonida/farmacologia , Células Espumosas/efeitos dos fármacos , Inflamação/tratamento farmacológico , Metabolismo dos Lipídeos/efeitos dos fármacos , Aterosclerose/tratamento farmacológico , Aterosclerose/metabolismo , Técnicas de Cultura de Células , Sobrevivência Celular/efeitos dos fármacos , Citocinas/metabolismo , Dexametasona/farmacologia , Células Espumosas/metabolismo , Glucocorticoides/farmacologia , Humanos , Inflamação/metabolismo , Lipídeos/fisiologia , Lipoproteínas LDL/metabolismo , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismoRESUMO
One of the major adverse effects of topical glucocorticoids is cutaneous atrophy often followed by development of resistance to steroids (tachyphylaxis). Previously we showed that after two weeks, interfollicular mouse keratinocytes acquired resistance to anti-proliferative effects of glucocorticoid fluocinolone acetonide (FA). One of the top genes activated by FA during tachyphylaxis was Klk6 encoding kallikrein-related peptidase 6, known to enhance keratinocyte proliferation. KLK6 was also strongly induced by chronic glucocorticoids in human skin. Double immunostaining showed that KLK6+ keratinocytes, localized in suprabasal layer of mouse skin, were frequently adjacent to proliferating 5-bromo-2'-deoxyuridine-positive basal keratinocytes. We used KLK6 knockout (KO) mice to evaluate KLK6 role in skin regeneration after steroid-induced atrophy. KLK6 KOs had thinner epidermis and decreased keratinocyte proliferation. The keratinocytes in wild type and KLK6 KO epidermis were equally sensitive to acute anti-proliferative effect of FA. However, the development of proliferative resistance during chronic treatment was reduced in KO epidermis. This was not due to the changes in glucocorticoid receptor (GR) expression or function as GR protein level and induction of GR-target genes were similar in wild type and KLK6 KO skin. Overall, these results suggest a novel mechanism of epidermal regeneration after glucocorticoid-induced atrophy via KLK6 activation.
Assuntos
Proliferação de Células/efeitos dos fármacos , Fluocinolona Acetonida/farmacologia , Calicreínas/metabolismo , Queratinócitos/efeitos dos fármacos , Adulto , Idoso , Animais , Atrofia/induzido quimicamente , Proliferação de Células/genética , Epiderme/metabolismo , Epiderme/patologia , Epiderme/fisiopatologia , Expressão Gênica/efeitos dos fármacos , Glucocorticoides/farmacologia , Humanos , Calicreínas/genética , Queratinócitos/metabolismo , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Camundongos Knockout , Pessoa de Meia-Idade , Regeneração , Pele/metabolismo , Pele/patologia , Pele/fisiopatologia , EsteroidesRESUMO
Paclitaxel (PTX) is among the most commonly used cancer drugs that cause chemotherapy-induced peripheral neuropathy (CIPN), a debilitating and serious dose-limiting side effect. Currently, no drugs exist to prevent CIPN, and symptomatic therapy is often ineffective. In order to identify therapeutic candidates to prevent axonal degeneration induced by PTX, we carried out a phenotypic drug screening using primary rodent dorsal root ganglion sensory neurons. We identified fluocinolone acetonide as a neuroprotective compound and verified it through secondary screens. Furthermore, we showed its efficacy in a mouse model of PTX-induced peripheral neuropathy and confirmed with four different cancer cell lines that fluocinolone acetonide does not interfere with PTX's antitumor activity. Our study identifies fluocinolone acetonide as a potential therapy to prevent CIPN caused by PTX.
Assuntos
Anti-Inflamatórios/uso terapêutico , Fluocinolona Acetonida/uso terapêutico , Paclitaxel/efeitos adversos , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/prevenção & controle , Animais , Animais Recém-Nascidos , Anti-Inflamatórios/farmacologia , Antineoplásicos Fitogênicos/efeitos adversos , Axônios/efeitos dos fármacos , Axônios/patologia , Linhagem Celular Tumoral , Células Cultivadas , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Embrião de Mamíferos , Feminino , Fluocinolona Acetonida/farmacologia , Gânglios Espinais/citologia , Camundongos , Fibras Nervosas/efeitos dos fármacos , Fibras Nervosas/patologia , Neurônios/efeitos dos fármacos , Ratos , Ratos Sprague-DawleyRESUMO
The aim of the current study was to develop and optimize Fluocinolone acetonide (FA) loaded nanostructured lipid carriers (NLC) and to evaluate its potential as topical delivery system for management of psoriasis. FA loaded NLCs were successfully developed by modified microemulsion method and optimized using 3-level Box-Behnken design. NLCs were evaluated for particle size, polydispersity index, zeta potential, drug entrapment efficiency and drug loading. Further X-ray diffraction (XRD) and Differential scanning calorimetry (DSC), in vitro release, in vitro skin distribution and stability study were also performed. Transmission electron microscopy confirmed spherical shape of prepared NLCs. Complete encapsulation of drug in the nanoparticles was confirmed by XRD and DSC. Release study showed prolonged drug release from the NLCs following Higuchi release kinetics and Zero order release kinetics, whereas pure FA suspension exhibited faster drug release following Zero order release kinetics with R(2) value of 0.995. Stability study confirmed that NLCs were stable for 3months at 4°C. Furthermore, in vitro skin distribution studies showed presence of significant amount of FA in the epidermal and dermal layer of skin when treated with FA loaded NLCs suspension while plain FA suspension showed significantly lesser amount of FA in the epidermis and dermis. Moreover, selective retention of FA in the epidermis might eliminate adverse side effects associated with systemic exposure. Thus FA loaded NLCs could be a potential system for psoriasis treatment but to create clinical value of the present system further studies are needed in clinically relevant models.
Assuntos
Portadores de Fármacos/química , Desenho de Fármacos , Fluocinolona Acetonida/química , Lipídeos/química , Nanopartículas/química , Psoríase/tratamento farmacológico , Pele/metabolismo , Administração Tópica , Animais , Química Farmacêutica , Portadores de Fármacos/metabolismo , Fluocinolona Acetonida/administração & dosagem , Fluocinolona Acetonida/farmacologia , Fluocinolona Acetonida/uso terapêutico , Cabras , Tamanho da Partícula , Pele/efeitos dos fármacos , SoftwareRESUMO
INTRODUCTION: Capping inflamed dental pulp tissue is currently a controversial issue. To reduce pulp inflammation and stimulate pulp healing, a pulp-capping material containing fluocinolone acetonide (PCFA) has been developed. This study was aimed to evaluate the inflammatory response and hard tissue formation of inflamed dental pulps of rat maxillary molars after capping with Dycal, mineral trioxide aggregate (MTA), or PCFA. METHODS: Sixty maxillary rat molars were exposed to the oral environment for 48 hours. The exposed pulps were randomly divided into 6 groups (n = 10) according to pulp-capping materials (Dycal, MTA, or PCFA) and time (8 or 30 days). The cavities were capped and sealed with Fuji II LC. The animals were sacrificed after 8 and 30 days. Histologic specimens were prepared and evaluated for inflammatory response and hard tissue formation. RESULTS: Eight days after pulp capping, all experimental groups showed disruption of the odontoblast layer in areas corresponding to the pulpal exposure. Acute inflammation was found in 80%, 60%, and 40% of samples in the Dycal, MTA, and PCFA groups, respectively. PCFA significantly decreased the pulp inflammation compared with Dycal. After 30 days, slight to moderate inflammation was found in all experimental groups. Hard tissue formation was found in 78%, 63%, and 100% of samples in the Dycal, MTA, and PCFA groups, respectively. No significant difference was found among the experimental groups. CONCLUSIONS: Pulp capping with PCFA reduced the inflammation and stimulated hard tissue formation in the exposed pulps of rat molars. It may be used as a pulp-capping agent in inflamed pulps.
Assuntos
Anti-Inflamatórios/farmacologia , Capeamento da Polpa Dentária , Polpa Dentária/efeitos dos fármacos , Fluocinolona Acetonida/farmacologia , Pulpite/terapia , Animais , Polpa Dentária/patologia , Masculino , Pulpite/tratamento farmacológico , Ratos , Ratos Wistar , CicatrizaçãoRESUMO
Respiration inhibitors such as the succinate dehydrogenase inhibitors (SDHIs) and the quinone outside inhibitors (QoIs) are fungicide classes with increasing relevance in gray mold control. However, recent studies have shown that dual resistance to both fungicide classes is a common trait in Botrytis cinerea populations from several hosts throughout the world. Resistance of B. cinerea to SDHIs is associated with several mutations in the sdhB, sdhC, and sdhD genes, while resistance to QoIs, in most cases, is associated with the G143A mutation in the cytb gene. The objective of the current study was to investigate the fitness and the competitive ability of B. cinerea field strains possessing one of the H272Y/R/L, N230I, or P225F sdhB substitutions and the G143A mutation of cytb. Fitness parameters measured were (i) mycelial growth and conidia germination in vitro, (ii) aggressiveness and sporulation capacity in vivo, (iii) sclerotia production in vitro and sclerotia viability under different storage conditions, and (iv) sensitivity to oxidative stress imposed by diquat treatments. The competitive ability of the resistant isolates was measured in the absence and presence of the SDHI fungicides boscalid and fluopyram selection pressure. The measurements of individual fitness components showed that the H272R/G143A isolates had the lower differences compared with the sensitive isolates. In contrast, the groups of H272Y/L/G143A, N230I/G143A, and P225F/G143A isolates showed reduced fitness values compared with the sensitive isolates. Isolates possessing only the cytb G143A substitution did not show any fitness cost. The competition experiments showed that, in the absence of fungicide selection pressure, after four disease cycles on apple fruit, the sensitive isolates dominated in the population in all the mixtures tested. In contrast, when the competition experiment was conducted under the selection pressure of boscalid, a gradual decrease in the frequency of sensitive isolates was observed, whereas the frequency of H272L and P225F isolates was increased. When the competition experiment was conducted in the presence of fluopyram, the sensitive isolates were eliminated even after the first disease cycle and the P225F mutants dominated in the population. Such results suggest that the sdhB mutations may have adverse effects on the mutants. The observed dominance of sensitive isolates in the competition experiments conducted in the absence of fungicides suggest that the application of SDHIs in alternation schemes may delay the selection or reduce the frequency of SDHI-resistant mutants.
Assuntos
Botrytis/genética , Farmacorresistência Fúngica , Proteínas Fúngicas/genética , Fungicidas Industriais/farmacologia , Malus/microbiologia , Doenças das Plantas/microbiologia , Benzoquinonas/antagonistas & inibidores , Botrytis/efeitos dos fármacos , Botrytis/crescimento & desenvolvimento , Botrytis/fisiologia , Fluocinolona Acetonida/farmacologia , Frutas/microbiologia , Proteínas Fúngicas/metabolismo , Genótipo , Testes de Sensibilidade Microbiana , Mutação de Sentido Incorreto , Micélio , Estresse Oxidativo , Fenótipo , Esporos Fúngicos , Succinato Desidrogenase/antagonistas & inibidoresRESUMO
BACKGROUND AND PURPOSE: Fluocinolone acetonide (FA) is commonly used as a steroidal anti-inflammatory drug. We recently found that in dental pulp cells (DPCs) FA has osteo-/odonto-inductive as well as anti-inflammatory effects. However, the mechanism by which FA induces these effects in DPCs is poorly understood. EXPERIMENTAL APPROACH: The effect of FA on the mineralization of DPCs during inflammatory conditions and the underlying mechanism were investigated by real-time PCR, Western blot, EMSA, histochemical staining, immunostaining and pathway blockade assays. KEY RESULTS: FA significantly inhibited the inflammatory response in LPS-treated DPCs not only by down-regulating the expression of pro-inflammation-related genes, but also by up-regulating the expression of the anti-inflammatory gene PPAR-γ and mineralization-related genes. Moreover, histochemical staining and immunostaining showed that FA could partially restore the expressions of alkaline phosphatase, osteocalcin and dentin sialophosphoprotein (DSPP) and mineralization in LPS-stimulated DPCs. Real-time PCR and Western blot analysis revealed that FA up-regulated DSPP and runt-related transcription factor 2 expression by inhibiting the expression of phosphorylated-NF-κB P65 and activating activator protein-1 (AP-1) (p-c-Jun and Fra-1). These results were further confirmed through EMSA, by detection of NF-κB DNA-binding activity and pathway blockade assays using a NF-κB pathway inhibitor, AP-1 pathway inhibitor and glucocorticoid receptor antagonist. CONCLUSIONS AND IMPLICATIONS: Inflammation induced by LPS suppresses the mineralization process in DPCs. FA partially restored this osteo-/odonto-genesis process in LPS-treated DPCs and had an anti-inflammatory effect through inhibition of the NF-κB pathway and activation of the AP-1 pathway. Hence, FA is a potential new treatment for inflammation-associated bone/teeth diseases.
Assuntos
Anti-Inflamatórios/farmacologia , Polpa Dentária/citologia , Fluocinolona Acetonida/farmacologia , NF-kappa B/antagonistas & inibidores , Fator de Transcrição AP-1/metabolismo , Adolescente , Adulto , Fosfatase Alcalina/genética , Fosfatase Alcalina/metabolismo , Calcificação Fisiológica/efeitos dos fármacos , Células Cultivadas , Citocinas/genética , Proteínas da Matriz Extracelular/genética , Proteínas da Matriz Extracelular/metabolismo , Humanos , Lipopolissacarídeos , Osteocalcina/metabolismo , PPAR gama/genética , Fosfoproteínas/genética , Fosfoproteínas/metabolismo , RNA Mensageiro/metabolismo , Sialoglicoproteínas/genética , Sialoglicoproteínas/metabolismo , Adulto JovemRESUMO
INTRODUCTION: The aim of this study was to investigate the role of the steroid fluocinolone acetonide on the proliferation and mineralization of human dental pulp cells (DPCs). The potential effect of fluocinolone acetonide on reparative dentin formation and the recovery of injured dental pulp were evaluated. METHODS: The proliferative effect of fluocinolone acetonide on DPCs was analyzed by cholecystokinin octapeptide assay and flow cytometry. The mineralized effect of fluocinolone acetonide was investigated by the detection of mineralization-related biomarkers including alkaline phosphatase (ALP), bone sialoprotein, and osteocalcin by using ALP histochemical staining, ALP activity, immunostaining, alizarin red staining, and reverse-transcriptase polymerase chain reaction. The molecules, including dentin sialophosphoprotein and Wnt4, involved in the process of mineralization were detected by real-time polymerase chain reaction and Western blot analysis. RESULTS: Low concentrations of fluocinolone acetonide (0.1-40 µmol/L) promoted the proliferation of DPCs. The flow cytometry results showed that the CD146-positive subpopulation of DPCs was significantly increased after treatment with fluocinolone acetonide at 1 and 10 µmol/L for 48 hours, respectively. The messenger RNA expression and activity of the early-stage mineralization marker ALP were evidently increased in fluocinolone acetonide-treated DPCs compared with the untreated control group, so did the middle-stage mineralization marker bone sialoprotein and the late-stage mineralization marker osteocalcin. Meanwhile, Wnt4 and the dentin-specific marker dentin sialophosphoprotein were obviously up-regulated by fluocinolone acetonide compared with the untreated controls. CONCLUSIONS: Fluocinolone acetonide can promote the proliferation of DPCs, especially for the CD146+ subpopulation. Fluocinolone acetonide can initiate the mineralization of DPCs and has the potential role in repairing injured pulp tissues.
Assuntos
Polpa Dentária/efeitos dos fármacos , Fluocinolona Acetonida/farmacologia , Glucocorticoides/farmacologia , Adolescente , Adulto , Fosfatase Alcalina/análise , Fosfatase Alcalina/efeitos dos fármacos , Antraquinonas , Biomarcadores/análise , Antígeno CD146/análise , Antígeno CD146/efeitos dos fármacos , Calcificação Fisiológica/efeitos dos fármacos , Técnicas de Cultura de Células , Proliferação de Células/efeitos dos fármacos , Corantes , Polpa Dentária/citologia , Polpa Dentária/lesões , Dentina Secundária/efeitos dos fármacos , Proteínas da Matriz Extracelular/análise , Proteínas da Matriz Extracelular/efeitos dos fármacos , Citometria de Fluxo/métodos , Humanos , Sialoproteína de Ligação à Integrina/análise , Sialoproteína de Ligação à Integrina/efeitos dos fármacos , Osteocalcina/análise , Osteocalcina/efeitos dos fármacos , Fosfoproteínas/análise , Fosfoproteínas/efeitos dos fármacos , Reação em Cadeia da Polimerase em Tempo Real , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Sialoglicoproteínas/análise , Sialoglicoproteínas/efeitos dos fármacos , Sincalida , Proteína Wnt4/análise , Proteína Wnt4/efeitos dos fármacos , Adulto JovemRESUMO
Fluocinolone acetonide intravitreal implant (Iluvien®) is an injectable, non-erodible, corticosteroid implant that is approved in several European countries for the treatment of chronic diabetic macular oedema (DMO). In analyses of two multinational trials in patients with DMO previously treated with macular laser photocoagulation, fluocinolone acetonide intravitreal implant 0.2 µg/day was significantly more efficacious than sham injection in improving visual acuity. At 24 months post injection, 29 % of fluocinolone acetonide intravitreal implant 0.2 µg/day recipients had an improvement in the best-corrected visual acuity (BCVA) letter score of ≥15 compared with 16 % in the sham injection group (p = 0.002) [primary endpoint]. Treatment benefit was most evident in the subgroup of patients whose duration of DMO was ≥3 years. In this subgroup at 36 months, 34 % of fluocinolone acetonide intravitreal implant 0.2 µg/day recipients had an increase in the BCVA score of ≥15, compared with 13 % of sham injection recipients (p < 0.001). Fluocinolone acetonide intravitreal implant recipients also had generally greater benefits than sham injection recipients on secondary endpoints. In patients who were phakic in the study eye at baseline, cataracts occurred in 82 % of fluocinolone acetonide intravitreal implant 0.2 µg/day recipients and 51 % of sham injection recipients. Overall, 37 % and 12 % of patients in the fluocinolone acetonide intravitreal implant and sham injection groups developed raised intraocular pressure (IOP), which was generally controlled with IOP-lowering drugs.
Assuntos
Retinopatia Diabética/tratamento farmacológico , Implantes de Medicamento , Fluocinolona Acetonida/administração & dosagem , Glucocorticoides/administração & dosagem , Edema Macular/tratamento farmacológico , Corpo Vítreo/efeitos dos fármacos , Fluocinolona Acetonida/química , Fluocinolona Acetonida/farmacologia , Glucocorticoides/química , Glucocorticoides/farmacologia , HumanosRESUMO
The Hedgehog signaling pathway is linked to a variety of diseases, notably a range of cancers. The first generation of drug screens identified Smoothened (Smo), a membrane protein essential for signaling, as an attractive drug target. Smo localizes to the primary cilium upon pathway activation, and this transition is critical for the response to Hedgehog ligands. In a high content screen directly monitoring Smo distribution in Hedgehog-responsive cells, we identified different glucocorticoids as specific modulators of Smo ciliary accumulation. One class promoted Smo accumulation, conferring cellular hypersensitivity to Hedgehog stimulation. In contrast, a second class inhibited Smo ciliary localization and signaling activity by both wild-type Smo, and mutant forms of Smo, SmoM2, and SmoD473H, that are refractory to previously identified Smo antagonists. These findings point to the potential for developing glucocorticoid-based pharmacological modulation of Smo signaling to treat mutated drug-resistant forms of Smo, an emerging problem in long-term cancer therapy. They also raise a concern about potential crosstalk of glucocorticoid drugs in the Hedgehog pathway, if therapeutic administration exceeds levels associated with on-target transcriptional mechanisms of glucocorticoid action.
Assuntos
Glucocorticoides/farmacologia , Proteínas Hedgehog/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Transdução de Sinais/efeitos dos fármacos , Anilidas/farmacologia , Animais , Células COS , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Chlorocebus aethiops , Interações Medicamentosas , Fluocinolona Acetonida/farmacologia , Glucocorticoides/química , Células HEK293 , Humanos , Camundongos , Células NIH 3T3 , Receptores Patched , Piridinas/farmacologia , Receptores de Superfície Celular/genética , Receptores de Superfície Celular/metabolismo , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptor SmoothenedRESUMO
The purpose of the current study was to determine whether a tropical ginger derived compound 1'-acetoxychavicol acetate (ACA), suppresses skin tumor promotion in K5.Stat3C mice. In a two-week study in which wild-type (WT) and K5.Stat3C mice were co-treated with either vehicle, ACA, galanga extract, or fluocinolone acetonide (FA) and tetradecanoyl phorbol acetate (TPA), only the galanga extract and FA suppressed TPA-induced skin hyperproliferation and wet weight. None of these agents were effective at suppressing p-Tyr705Stat3 expression. However, ACA and FA showed promising inhibitory effects against skin tumorigenesis in K5.Stat3C mice. ACA also suppressed phospho-p65 NF-κB activation, suggesting a potential mechanism for its action.
Assuntos
Álcoois Benzílicos/farmacologia , Transformação Celular Neoplásica/efeitos dos fármacos , Fator de Transcrição STAT3 , Neoplasias Cutâneas , 9,10-Dimetil-1,2-benzantraceno/toxicidade , Alpinia/química , Animais , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Fluocinolona Acetonida/farmacologia , Zingiber officinale/química , Humanos , Camundongos , Camundongos Transgênicos , NF-kappa B/antagonistas & inibidores , NF-kappa B/metabolismo , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Fator de Transcrição STAT3/genética , Fator de Transcrição STAT3/metabolismo , Neoplasias Cutâneas/induzido quimicamente , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/patologia , Acetato de Tetradecanoilforbol/farmacologiaRESUMO
Glucocorticoids (GCs) are widely used in chemotherapy of hematological malignancies, particularly leukemia. Their effect is mediated by glucocorticoid receptor (GR), a well-known transcription factor. Besides their therapeutic impact, GCs may cause a number of side effects leading to various metabolic complications. The goal of immediate interest is testing glucocorticoid analogs capable of induction/enhancement of GR transrepression, but preventing GR dimerization and transactivation leading to side effects. In this work we have investigated effects of a promising new selective GR agonist, 2-(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride (CpdA), on CEM and K562 leukemia cells. Both cell lines express functional GR. CpdA compared with the glucocorticoid fluocinolone acetonide (FA) exerted more prominent cytostatic and apoptotic effects on the cells. Both cell lines exhibited sensitivity to CpdA, demonstrating a good correlation with the effects of FA on cell growth and viability. In contrast to FA, CpdA did not induce GR transactivation evaluated by no obvious increase in expression of GR target (and dependent) gene FKBP51. At the same time, luciferase assay showed that CpdA efficiently activated transrepression of NF-κB and AP-1 factors. We also evaluated the effect of combined action of CpdA and the proteasome inhibitor Bortezomib. The latter induced a caspase-dependent apoptosis in both T-cell leukemia cell lines. By treatment of CEM cells with different CpdA/GC and Bortezomib doses, we have designed a protocol where CpdA shows potentiating effect on Bortezomib cytotoxic activity. Generally, the present work characterizes a novel non-steroid GR ligand, CpdA, as a promising compound for possible application in leukemia chemotherapy.
Assuntos
Acetatos/farmacologia , Apoptose/efeitos dos fármacos , Citostáticos/farmacologia , Leucemia/metabolismo , Receptores de Glucocorticoides/agonistas , Tiramina/análogos & derivados , Ácidos Borônicos/farmacologia , Bortezomib , Linhagem Celular Tumoral , Fluocinolona Acetonida/farmacologia , Humanos , Células K562 , Ligantes , NF-kappa B/genética , NF-kappa B/metabolismo , Pirazinas/farmacologia , Receptores de Glucocorticoides/metabolismo , Proteínas de Ligação a Tacrolimo/genética , Proteínas de Ligação a Tacrolimo/metabolismo , Fator de Transcrição AP-1/genética , Fator de Transcrição AP-1/metabolismo , Tiramina/farmacologiaRESUMO
INTRODUCTION: Diabetes mellitus with its ophthalmic complications is the major cause for legal blindness in industrialized countries. Diabetic macular edema and its complex pathophysiology as part of diabetic retinopathy are the leading cause of vision loss among diabetic patients. In recent years, treatment options have developed involving the intravitreal applications of several compounds. AREAS COVERED: Current treatment options for diabetic macular edema including laser therapy and scientific basis of new drugs are discussed. Possible benefits and drawbacks of these new approaches are addressed. EXPERT OPINION: In recent years, new drugs against retinal diseases have been developed consisting mainly of steroid or anti-vascular endothelial growth factor compounds. Targeting macular edema, the second shows a possible therapeutic role in the proliferative form of diabetic retinopathy, requiring further investigation. New biodegradable delivery systems show an advantage in sustaining effective compound concentrations for longer times and have positive impact on safety profile and cost-effectiveness of the drug, a factor of grave importance when considering the future of any new drug in the market. All these new therapeutic approaches alone or in combination with the existing treatments have to demonstrate their efficacy and safety in diabetic retinopathy in current and future trials.